The Securities and Exchange Commission has not necessarily
reviewed the information in this filing and has not determined
if it is accurate and complete.
| |||||||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ALKERMES PLC | SHS | G01767105 | 157,185,000 | 3,000,000 | SH | SOLE | 3,000,000 | 0 | 0 | ||
| ALTO NEUROSCIENCE INC | COM SHS | 02157Q109 | 71,865,142 | 2,723,196 | SH | SOLE | 2,723,196 | 0 | 0 | ||
| AMYLYX PHARMACEUTICALS INC | COM | 03237H101 | 101,474,000 | 5,650,000 | SH | SOLE | 5,650,000 | 0 | 0 | ||
| AN2 THERAPEUTICS INC | COM | 037326105 | 14,199,011 | 2,933,680 | SH | SOLE | 2,933,680 | 0 | 0 | ||
| ASSEMBLY BIOSCIENCES INC | COM NEW | 045396207 | 38,884,200 | 1,415,000 | SH | SOLE | 1,415,000 | 0 | 0 | ||
| AVALO THERAPEUTICS INC | COM NEW | 05338F306 | 18,818,535 | 1,018,319 | SH | SOLE | 1,018,319 | 0 | 0 | ||
| CELLDEX THERAPEUTICS INC NEW | COM NEW | 15117B202 | 50,233,500 | 1,350,000 | SH | SOLE | 1,350,000 | 0 | 0 | ||
| CENTURY THERAPEUTICS INC | COM | 15673T100 | 21,304,347 | 8,695,652 | SH | SOLE | 8,695,652 | 0 | 0 | ||
| COGENT BIOSCIENCES INC | COM | 19240Q201 | 118,035,000 | 3,050,000 | SH | SOLE | 3,050,000 | 0 | 0 | ||
| DAMORA THERAPEUTICS INC | COM NEW | 36322Q206 | 50,433,390 | 1,939,000 | SH | SOLE | 1,939,000 | 0 | 0 | ||
| DEFINIUM THERAPEUTICS INC | COM SHS | 24477V105 | 94,080,000 | 2,000,000 | SH | SOLE | 2,000,000 | 0 | 0 | ||
| EDITAS MEDICINE INC | COM | 28106W103 | 28,800,360 | 8,889,000 | SH | SOLE | 8,889,000 | 0 | 0 | ||
| ENLIVEN THERAPEUTICS INC | COM | 29337E102 | 166,206,250 | 3,275,000 | SH | SOLE | 3,275,000 | 0 | 0 | ||
| EYEPOINT INC | COM NEW | 30233G209 | 65,780,000 | 4,600,000 | SH | SOLE | 4,600,000 | 0 | 0 | ||
| HELIX ACQUISITION CORP III | USD CL A ORD SHS | G4444S107 | 5,320,000 | 500,000 | SH | SOLE | 500,000 | 0 | 0 | ||
| INFLARX NV | COM | N44821101 | 16,352,000 | 7,300,000 | SH | SOLE | 7,300,000 | 0 | 0 | ||
| INHIBIKASE THERAPEUTICS INC | COM NEW | 45719W205 | 10,956,901 | 5,397,488 | SH | SOLE | 5,397,488 | 0 | 0 | ||
| KYMERA THERAPEUTICS INC | COM | 501575104 | 28,667,500 | 250,000 | SH | SOLE | 250,000 | 0 | 0 | ||
| LB PHARMACEUTICALS INC | COM SHS | 50180M108 | 48,682,500 | 1,500,000 | SH | SOLE | 1,500,000 | 0 | 0 | ||
| LEONABIO INC | COM | 04746L203 | 4,267,818 | 464,398 | SH | SOLE | 464,398 | 0 | 0 | ||
| NUVALENT INC | COM | 670703107 | 12,350,000 | 100,000 | SH | SOLE | 100,000 | 0 | 0 | ||
| PEPGEN INC | COM | 713317105 | 8,055,000 | 4,475,000 | SH | SOLE | 4,475,000 | 0 | 0 | ||
| PERSPECTIVE THERAPEUTICS INC | COM NEW | 46489V302 | 21,608,427 | 6,336,782 | SH | SOLE | 6,336,782 | 0 | 0 | ||
| PHARVARIS N V | COM | N69605108 | 49,276,500 | 1,425,000 | SH | SOLE | 1,425,000 | 0 | 0 | ||
| RELAY THERAPEUTICS INC | COM | 75943R102 | 224,520,000 | 12,000,000 | SH | SOLE | 12,000,000 | 0 | 0 | ||
| RELMADA THERAPEUTICS INC | COM | 75955J402 | 9,861,000 | 1,425,000 | SH | SOLE | 1,425,000 | 0 | 0 | ||
| RESEARCH ALLIANCE CORP III | ORD SHS CL A | G75226103 | 5,350,000 | 500,000 | SH | SOLE | 500,000 | 0 | 0 | ||
| SAB BIOTHERAPEUTICS INC | COM NEW | 78397T202 | 11,193,000 | 2,870,000 | SH | SOLE | 2,870,000 | 0 | 0 | ||
| SPYRE THERAPEUTICS INC | COM NEW | 00773J202 | 75,177,661 | 846,786 | SH | SOLE | 846,786 | 0 | 0 | ||
| TANGO THERAPEUTICS INC | COM | 87583X109 | 70,335,000 | 2,250,000 | SH | SOLE | 2,250,000 | 0 | 0 | ||
| TYRA BIOSCIENCES INC | COM | 90240B106 | 59,887,500 | 1,875,000 | SH | SOLE | 1,875,000 | 0 | 0 | ||
| VISTAGEN THERAPEUTICS INC | COM | 92840H400 | 630,228 | 2,788,620 | SH | SOLE | 2,788,620 | 0 | 0 | ||
| ZURA BIO LTD | CLASS A ORD SHS | G9TY5A101 | 19,175,000 | 3,250,000 | SH | SOLE | 3,250,000 | 0 | 0 | ||